Title
Tyk2 is a therapeutic target for psoriasis-like skin inflammation

Author(s)
Ishizaki, Masayuki; Muromoto, Ryuta; Akimoto, Toshihiko; Sekine, Yuichi; Kon, Shigeyuki; Diwan, Manish; Maeda, Hiroaki; Togi, Sumihito; Shimoda, Kazuya; Oritani, Kenji; Matsuda, Tadashi

Citation
International Immunology

Issue Date
2013-12-17

Doc URL
http://hdl.handle.net/2115/57647

Rights
This is a pre-copy-editing, author-produced PDF of an article accepted for publication in International Immunology following peer review. The definitive publisher-authenticated version "International Immunology 2011 23(9):575-582" is available online at: http://intimm.oxfordjournals.org/content/early/2013/12/16/intimm.dxt062.long

Type
article (author version)

Additional Information
There are other files related to this item in HUSCAP. Check the above URL.

File Information
Tyk2_Matsuda_T_2013_Supple.pdf (Supplementary Data)
Supplementary Fig. 1. Dermal inflammatory cells are diminished by Tyk2 deficiency in IL-23-induced skin inflammation. Dermal cells were isolated from digested Tyk2+/+ and Tyk2–/– ear skin on day 4, and subjected to flow cytometry. The absolute number of inflammatory cells from uniformly collected ear tissue by biopsy punch is shown. Data represents mean ± SD (n=5). **p<0.01, ***p<0.001 compared with BSA-injected mice group; ###p<0.001 compared with Tyk2–/– mice group. Similar results were obtained in two independent experiments. (B) Tyk2+/+ and Tyk2–/– mice were intradermally injected with 1 µg/ear of IL-23 or BSA for every day. mRNAs were prepared from the ear draining LN of Tyk2+/+ and Tyk2–/– mice on day 4, and subjected to quantitative RT-PCR with the indicated primers. Gene expression level was normalized by GAPDH expression. Data represents mean ± SD (n=5). *p<0.05, **p<0.01 compared with BSA-injected mice group; *p<0.05, ###p<0.01 compared with Tyk2–/– mice group. Similar results were obtained in two independent experiments.
Supplementary Fig. 2. Involvement of Tyk2 in IL-23-induced prolonged skin inflammation. (A) The ear pinna of Tyk2+/+ and Tyk2−/− mice was intradermally injected with 1 µg/ear of IL-23 or BSA on an intermissive schedule, 5-times in 10 days. Ear swelling was evaluated on the days as indicated. (B) Epidermal hyperplasia was evaluated by measuring the epidermal thickness by imaging analysis. Data represents mean ± SD (n=5). *p<0.05, **p<0.01, ***p<0.001 compared with BSA-injected mice group; ##p<0.01, ###p<0.001 compared with Tyk2−/− mice group. (C) Representative H&E stained histological features of IL-23-treated ear pinna from Tyk2+/+ and Tyk2−/− mice. Scale bar, 100 µm. (D) Flow cytometry analysis of the dermal cells isolated from pooled Tyk2+/+ and Tyk2−/− ear skin by the intermissive injection. Surface markers of major inflammatory cells were analyzed with fluorescent-labeled specific antibodies. Similar results were obtained in two independent experiments.
Supplementary Fig. 3. Tyk2 directly regulates IL-22-induced skin inflammation. (A) IL-22-dependent inflammatory molecules expression in ear pinna. IL-22 was injected into the ear pinna, then the pinna was harvested from sacrificed Tyk2+/+ and Tyk2−/− mice at 1, 3 and 6 h after the single injection. Data represents mean ± SD (n=5). *p<0.05, **p<0.01, ***p<0.001 compared with Tyk2+/+ mice group. (B) IL-22-dependent keratinocyte proliferation marker K16 and antimicrobial peptide expressions in the ear pinna. The ear pinna from Tyk2+/+ and Tyk2−/− mice was harvested at 1, 3 and 6 h after the single IL-22 injection. Similar results were obtained in two independent experiments. (C) Epidermal hyperplasia is not depend on IL-17A in IL-23-induced skin inflammation. Anti-IL-17A neutralization antibody (0.1 mg/mouse) was intraperitoneally injected on day 0, then the ear pinna of Tyk2+/+ mice was intradermally injected with 1 µg/ear of IL-23 or BSA for 4 consecutive days. Epidermal thickness were evaluated on day 4. Data represents mean ± SD (n=5). ***p<0.001 compared with BSA. Similar results were obtained in two independent experiments.